Amgen Inc. reaffirmed revenue guidance for the year 2022. The company reaffirmed going to 2022 revenue ranges despite by headwinds.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
309.1 USD | -0.09% | -1.69% | +7.42% |
05-22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
05-22 | Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.42% | 166B | |
+40.45% | 723B | |
+34.28% | 595B | |
-3.67% | 369B | |
+20.45% | 332B | |
+2.99% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
+0.30% | 168B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen Inc. Reaffirms Revenue Guidance for the Year 2022